Karolinska Development company Modus Therapeutics announces appointment of Ellen K. Donnelly, Ph.D. as CEO
STOCKHOLM - APRIL 24, 2017. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces its portfolio company Modus Therapeutics AB, a company focused on innovative treatments for patients with sickle cell disease (SCD), has appointed Ellen K. Donnelly, PhD, as Chief Executive Officer.
Details from the Modus announcement follow:
Dr. Donnelly joins Modus Therapeutics from Pfizer, Inc., where she has held numerous leadership positions in Clinical Operations; Project and Portfolio Management; and Research. Most recently she was responsible for Clinical Operations for Pfizer's Neuroscience and Pain therapeutic area. Dr. Donnelly also brings biotech and consulting experience to the CEO role, having worked in positions within U.S. biotech and management consulting prior to her time at Pfizer. Dr. Donnelly received her Ph.D. from Yale University.
Chairman of Modus Therapeutics, Björn Sjöstrand, said: "We are pleased to welcome Dr. Donnelly as CEO and are confident her background and broad experience in global drug development will help drive Modus Therapeutics forward, as we continue patient recruitment in our Phase II clinical study with sevuparin for SCD."
Dr. Donnelly added: "I am thrilled to join Modus at this important time for the Company. SCD is a crippling disease affecting many hundreds of thousands of patients around the world and Modus has a clear plan to address patients' pain through both hospital and home-based treatment options. The high unmet medical needs of SCD patients require novel therapeutic options, and I look forward to working with patients and their families to ensure the best possible outcomes for this disease, as we further develop sevuparin for SCD."
Viktor Drvota, Deputy CEO and Chief Investment Officer of Karolinska Development, said: "We welcome Dr. Donnelly as CEO of Modus Therapeutics, and are confident her extensive clinical development knowledge in the SCD field and her broader corporate experience will be key to the Company's future success. Modus is on track and financed to deliver data from its Phase II clinical study in early 2018, providing the first opportunity for one of our therapeutic company portfolio to meet an important clinical value-inflection point."
Dr. Donnelly is based in Stockholm and will take up her appointment on 25 April 2017. She succeeds Dr. Christina Herder.
For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail:email@example.com
Viktor Drvota, Deputy CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: firstname.lastname@example.org
David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev@citigatedr.co.uk
TO THE EDITORS
About Modus Therapeutics
Modus Therapeutics is a clinical-stage drug development company developing new pharmaceutical therapies to restore impaired blood flow and oxygen transport in rare diseases with large unmet medical need. The Company's most advanced candidate, sevuparin, is currently being evaluated in a Phase II clinical trial in sickle cell disease (SCD). Repeated painful crises in SCD, so-called vaso-occlusive crises ("VOC"), leads to loss of vital organ function and often significantly reduced life span. Modus Therapeutics is based in Stockholm. The Company's major shareholders are KDev Investments AB (an investment fund jointly owned by Karolinska Development AB and Rosetta Capital), Östersjöstiftelsen (The Foundation for Baltic and East European Studies), and Praktikerinvest PE AB. For more information, please visit www.modustx.com
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire
Följ NASDAQ OMX
Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.
Senaste pressmeddelandena från NASDAQ OMX
Hitachi Vantara Unveils New Turnkey IoT Appliance, Powered by Lumada Software19.9.2017 17:50 | Pressmeddelande
Hitachi IoT Appliance Accelerates the Time to Insight and Value of IoT Solution Deployments for Industrial and Commercial Enterprise Customers LAS VEGAS, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Hitachi Vantara, a wholly owned subsidiary of Hitachi, Ltd. (TSE:6501), today unveiled a new appliance for internet of things (IoT) deployments: Hitachi IoT Appliance, powered by Lumada, Hitachi's IoT platform. Delivered as a turnkey system, the appliance's "hyperconverged meets microservices" architecture combines Hitachi's best-in-class storage and compute with industry-leading networking technologies and comes fully integrated with Hitachi's latest Lumada software. Hitachi IoT Appliance has been fully pre-architected and pre-validated to provide a plug-and-play solution that can be easily deployed and production-ready in under an hour. This gives users the ability to more rapidly connect, monitor and extract actionable insights from their business and industrial assets. Fo
Hitachi Aims To Disrupt Industrial IoT Platform Market With New Commercial Lumada Software Stack19.9.2017 17:50 | Pressmeddelande
Fully Enhanced and Now Available as a Standalone Offering for IoT Developers and Architects, Hitachi's Lumada Provides an Intelligent, Composable Platform That Delivers Faster Time to Insight and Business Value for Industrial and Enterprise Customers TOKYO and LAS VEGAS, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Hitachi Ltd. (TSE:6501) and Hitachi Vantara, today jointly announced Hitachi's first commercial Lumada internet of things (IoT) platform offering. Now in its v2.0 release, the Lumada IoT platform has been fully updated with an elegant, portable architecture that enables it to run both on-premises or in the cloud and to support industrial IoT deployments both at the edge and in the core. The new software stack is designed to help customers quickly and easily gain insights, predictions and recommendations from their data, and can be easily adapted to support mid-to-large-scale environments. Lumada's integrated advanced analytics have also b
Hitachi Introduces Hitachi Vantara: A New Digital Company Committed to Solving the World's Toughest Business and Societal Challenges19.9.2017 17:45 | Pressmeddelande
Company Formed to Help Customers Achieve Unprecedented Outcomes by Tapping the Full Potential of Their Data TOKYO and LAS VEGAS, Sept. 19, 2017 (GLOBE NEWSWIRE) -- Hitachi, Ltd. (TSE:6501) ("Hitachi") today launched Hitachi Vantara, a new business entity to leverage the broad portfolio of innovation, development and experience from across Hitachi Group companies to deliver data-driven solutions for commercial and industrial enterprises. This new company will unify the operations of Hitachi Data Systems, Hitachi Insight Group, and Pentaho into a single integrated business as Hitachi Vantara to capitalize on Hitachi's social innovation capability in both operational technologies (OT) and information technologies (IT). More Than a Century of OT Expertise Combined with IT Trusted by the World's Largest Enterprises Hitachi has been a leader in OT for industries such as finance, government, manufacturing, power/energy and transportation
Sigma Designs Launches Z-Wave Smart Home Maker Challenge19.9.2017 17:00 | Pressmeddelande
Sigma Designs and Make: Debut Smart Home Design Mission at World Maker Faire 2017 in New York Celebrating Maker Community Creativity, Collaboration and Inspiring Z-Wave App Design FREMONT, Calif., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Sigma Designs® (NASDAQ:SIGM), a leading provider of intelligent system-on-chip (SoC) solutions for Connected Smart TV platforms and Smart home IoT, and Make:, leader of the Maker movement and producer of the popular Maker Faire events, today announces a smart home Z-Wave app design contest for Makers and Developers. Sigma Designs launches the Z-Wave Smart Home Maker Challenge today in cooperation with Make: and in unison with the flag-ship World Maker Faire that takes place in New York City September 23-24th. The smart home design competition will be hosted on the all-new Maker Share community platform where participants will have the opportunity to submit their idea for a smart home application that would turn their dream sm
3Gtms Names Managing Director of EMEA19.9.2017 16:00 | Pressmeddelande
Chris van der Harst will lead growth of unique TMS solution SHELTON, Conn., Sept. 19, 2017 (GLOBE NEWSWIRE) -- 3Gtms, Inc., a global provider of Tier 1 transportation management software (TMS), announced that it has named Chris van der Harst to the new position of managing director, EMEA. In this position, van der Harst will lead 3Gtms' overseas efforts from its EMEA headquarters in Utrecht, The Netherlands. He will be responsible for growing 3Gtms' market share among 3PLs and mid-large sized shippers, as well as ensuring 3Gtms' industry-leading satisfaction rate is upheld among all customers. 3Gtms' robust TMS gives 3PLs and shippers the most powerful and intuitive system for over-the-road and intermodal freight, along with best-in-class rating and optimization. The modern design enables flexible, seamless handling of the most complicated shipping requirements, covering the complete order-to-cash process. A 30-year supply cha
Novavax Initiates Phase 1/2 Trial of NanoFlu(TM) Vaccine in Older Adults19.9.2017 15:05 | Pressmeddelande
Recently published NanoFlu(TM) preclinical data provide strong rationale for Phase 1/2 clinical trial based on robust antibody titers and improved protective responses against both current and drifted strains Data from trial expected by the end of 2017 GAITHERSBURG, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced the enrollment of the first participant in a Phase 1/2 clinical trial of its nanoparticle influenza vaccine candidate including its proprietary Matrix-M(TM) adjuvant (NanoFlu(TM)) in older adults. The trial is a randomized, observer-blinded, active comparator-controlled trial in approximately 330 healthy older adults. The primary objective of the trial is to assess the safety and immunogenicity of two concentrations (15 µg or 60 µg) of NanoFlu compared to a licensed influenza vaccine, Fluzone® High-Dose (Fluzone HD).
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum